183 related articles for article (PubMed ID: 29072978)
1. Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
Berchuck A; Secord AA; Moss HA; Havrilesky LJ
J Clin Oncol; 2017 Dec; 35(36):3999-4002. PubMed ID: 29072978
[No Abstract] [Full Text] [Related]
2. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
3. Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
Chan JK; Liang SY; Kapp DS; Chan JE; Herzog TJ; Coleman RL; Monk BJ; Richardson MT
Gynecol Oncol; 2020 Dec; 159(3):604-606. PubMed ID: 32994055
[No Abstract] [Full Text] [Related]
4. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
5. [Poly (ADP-Ribose) Polymerase Inhibitors--Current Status and Future Developments].
Yoshida H; Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):193-7. PubMed ID: 27093730
[No Abstract] [Full Text] [Related]
6. Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020.
Madariaga A; Bonilla L; McMullen M; Oza AM; Lheureux S
Int J Gynecol Cancer; 2020 Aug; 30(8):1256-1257. PubMed ID: 32646863
[No Abstract] [Full Text] [Related]
7. [PARP inhibitors in first-line of ovarian cancers].
Rodrigues M
Bull Cancer; 2020 Jan; 107(1):4-5. PubMed ID: 31928735
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Gonzalez R; Havrilesky LJ; Myers ER; Secord AA; Dottino JA; Berchuck A; Moss HA
Gynecol Oncol; 2020 Nov; 159(2):483-490. PubMed ID: 32863036
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
Graybill WS; Pothuri B; Chase DM; Monk BJ
Gynecol Oncol; 2017 Jul; 146(1):11-15. PubMed ID: 28392129
[No Abstract] [Full Text] [Related]
12. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract][Full Text] [Related]
13. New Therapies for Ovarian Cancer.
Armstrong DK
J Natl Compr Canc Netw; 2018 May; 16(5S):632-635. PubMed ID: 29784743
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
16. The rise of genomic profiling in ovarian cancer.
Previs RA; Sood AK; Mills GB; Westin SN
Expert Rev Mol Diagn; 2016 Dec; 16(12):1337-1351. PubMed ID: 27828713
[TBL] [Abstract][Full Text] [Related]
17. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
18. Diverse mechanisms of PARP inhibitor resistance in ovarian cancer.
Wakefield MJ; Nesic K; Kondrashova O; Scott CL
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188307. PubMed ID: 31381953
[No Abstract] [Full Text] [Related]
19. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors for ovarian cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
